MedWatch

ALK predicts 8–12 percent revenue growth in 2022

Allergy company ALK is expecting to reach an increase in revenue of 8–12 percent in local currencies in 2022, the company states in connection with full-year report on Tuesday.

Photo: ALK / PR

On Tuesday morning, ALK released the last quarterly figures for 2021, and therefore also for the entire year. In connection with the publication of the results, the allergy company has upgraded its guidance for the current financial year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs